-
AKLRD awarded £675,000 grant from Innovate UK
pharmaceutical-technology
February 19, 2019
The UK Government’s innovation agency Innovate UK has awarded AKL Research and Development (AKLRD) £675,000 linked to the potential of its investigational medicine APPA for osteoarthritis......
-
Study examines long-term opioid use in patients with severe osteoarthritis
worldpharmanews
February 01, 2019
Long-term use of prescription opioids for the treatment of chronic pain carries the risk of dependence and other serious harms
-
Genetic study reveals possible new routes to treating osteoarthritis
worldpharmanews
January 23, 2019
In the largest genetic study of osteoarthritis have uncovered 52 new genetic changes linked to the disease, which doubles the number of genetic regions associated with the disabling condition.
-
Mundipharma to Bring World's First Gene Therapy for Osteoarthritis to Nine More Countries in APAC
firstwordpharma
January 17, 2019
According to the World Health Organisation, osteoarthritis is the single most common cause of disability in older people with an estimated 10%-15% of all people over 60 suffering from it. Currently, its prevalence is increasing.
-
Mundipharma to bring world's first gene therapy for knee osteoarthritis
.biospectrumasia
November 20, 2018
Mundipharma will be responsible for the development, marketing and distribution of Invossa to medical professionals and
-
Boston Startup Centrexion by Pfizer's Ex-CEO grants $67M for Ph3 Osteoarthritis Pain Drug
biospace
January 03, 2018
Centrexion Therapeutics closed on a Series D financing worth $67 million to develop its knee osteoarthritis (OA) drug in Phase III.
-
Cocoon Biotech Teams Up With Camargo
contractpharma
February 13, 2017
Will focus on Cocoon's pipeline of osteoarthritis products
-
Osteoarthritis – opportunity analysis and forecasts to 2024
pharmaasia
January 20, 2017
Rapid growth in the Osteoarthritis (OA) market within the seven major markets is expected by 2024.